Mylan could be facing another issue when it comes to the EpiPen, a drug used to treat severe allergic reactions that …
Generic drug maker Mylan NV reported first-quarter profit just above expectations, helped by demand for products it gained through the acquisition of Swedish drugmaker Meda, even as sales of its controversial EpiPen allergy shot declined. …
Mylan said it told the FDA about the issue months ago and remains ... “If a particular store is currently out of stock, other locations may have it available,” he said. …
Compensation often includes stock and option grants that the CEO may not receive ... Margaret Keane Synchrony Financial $13.5 million Change: Up 32 percent 10. …
Shares of Mylan N.V.’s MYL were up 7.2% after the company beat expectations in the fourth-quarter 2016 and provided a strong outlook for 2017 amid challenging conditions. The company reported fourth-quarter 2016 earnings of $1.57 per …
NEW YORK (CNNMoney.com) -- Mylan Pharmaceuticals' stock plunged after the drugmaker said it was purchasing the generic arm of German drug giant Merck KGaA. Mylan (down $2.49 to $19.91, Charts) stock fell more than 13 percent …
Of the company's shareholders who voted, 98 percent approved the transaction. Yet not all stockholders were aware of the tax implications. John Kablach, 85, of Smithton only recently found out he would have to pay capital gains on his Mylan …
(AP Photo/Mark Zaleski, File) Shares of Mylan are edging up before the opening bell after the pharmaceutical company went ahead with its hostile, $27.14 billion bid for Perrigo. With the cash and stock offer made directly to Perrigo's …
Mylan's shares dropped after it said that delays in launching key new drugs and lower prices for generics in the United States will hurt its profitability this and next year. Fred Katayama reports.